Liver

Post Views: 319
Cancer Liver Oceania RESEARCHER PROFILE

Liver cancer biomarkers, risk prediction & progression

By Bench Side Story — 1 month ago

Dr. Rodrigo Carlessi is an expert in Cancer Genomics and Molecular Biology, with an extensive track record in liver cancer research. He leads the Cancer Genomics Group within the Liver Disease and Regeneration Laboratory at the Curtin Medical Research Institute. He has an impressive publication record, with 43 manuscripts that have collectively garnered over 2,680 citations. His research leverages cutting-edge genomics and transcriptomics technologies, as well as long-read DNA sequencing, to explore mechanisms, identify biomarkers, and develop therapeutic targets in liver disease and cancer.

Post Views: 1,181
CASE STUDY Exercise Liver Oceania Policy and/or position statement

CASE STUDY Role of Exercise in Metabolic Associated Fatty Liver Disease

By Bench Side Story — 1 year ago

Dr. Shelley Keating AES AEP* is an Accredited Exercise Physiologist, a researcher, and a senior lecturer at the School of Human Movement and Nutrition Sciences at the University of Queensland in Brisbane, Australia. Dr. Keating’s research primarily focuses on the role of exercise in the management of metabolic dysfunction associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease. MASLD affects a significant portion of the global adult population, with many individuals unaware of their condition.

Post Views: 900
Exercise Liver Oceania RESEARCHER PROFILE

Exercise therapy for metabolic dysfunction-associated steatotic liver disease

By Bench Side Story — 1 year ago

Dr Shelley Keating is a Senior Lecturer in Clinical Exercise Physiology and Accredited Exercise Physiologist from the School of Human Movement and Nutrition Sciences at the University of Queensland. With a strong grounding in exercise metabolism and body composition, Dr Keating’s research centres on the utility of exercise as a therapy for obesity and related cardiometabolic conditions, notably metabolic dysfunction-associated steatotic liver disease (MASLD).

Scroll to top